Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Brentuximab vedotin and CHP for PTCL: upcoming Phase II trial

Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH discusses the upcoming Phase II trial (NCT04569032) assessing brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma (excluding systemic anaplastic large cell lymphoma (sALCL)) with less than 10% CD30 expression, following the success of the Phase III ECHELON-2 trial. The trial will have two arms, including 40 patients with CD30 less than 10% and 40 patients with undetectable CD30 who will be assessed for a total of 6 cycles. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research funding: MEI Pharma, Debiopharm Group, Regeneron
Membership on an entity’s Board of Directors or advisory committees: Verastem, Seattle Genetics